Advanced in Streptococcal Group B Infection

Dr. Ronald G. Nahass

Infectious Disease
105 Raider Blvd, Suite 101, 
Hillsborough, NJ 
On Staff At
Accepting New Patients
Offers Telehealth
38 Years of Experience
Advanced in Streptococcal Group B Infection
105 Raider Blvd, Suite 101, 
Hillsborough, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ronald Nahass is an Infectious Disease provider in Hillsborough, New Jersey. Dr. Nahass has been practicing medicine for over 38 years and is rated as an Advanced provider by MediFind in the treatment of Streptococcal Group B Infection. His top areas of expertise are Hepatitis C, Hepatitis, Hepatitis B, and Lyme Disease. Dr. Nahass is currently accepting new patients.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Medicine And Dentistry Of New Jersey
Residency
University Hospital - UMDNJ
Specialties
Infectious Disease
Licenses
Internal Medicine in NJ
Board Certifications
Infectious Disease, 1988
Internal Medicine, 1985
Fellowships
Robert Wood Johnson University Hospital
Hospital Affiliations
Robert Wood Johnson University Hospital - Somerset
University Medical Center Of Princeton At Plainsboro
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

ID Care, Hillsborough
105 Raider Blvd, Suite 101, Hillsborough, NJ 08844
Other Locations
ID Care, Somerset
49 Veronica Avenue, Suite 102, Somerset, NJ 08873
ID Care, Princeton
10 Forrestal Road South, Suite 203, Princeton, NJ 08540

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection
A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drugs: AB-729, Peg-IFN?-2a
Study Phase: Phase 2
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

46 Total Publications

Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS-CoV-2 Infection With and Without Diabetes.
Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS-CoV-2 Infection With and Without Diabetes.
Journal: Journal of medical virology
Published: October 12, 2024
Similar Doctors
Distinguished in Streptococcal Group B Infection
Dr. Sukrut A. Dwivedi
Infectious Disease
Distinguished in Streptococcal Group B Infection
Dr. Sukrut A. Dwivedi
Infectious Disease

Id Care LLC

105 Raider Blvd, Suite 101, 
Hillsborough, NJ 
 (7.6 miles away)
908-281-0221
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sukrut Dwivedi is an Infectious Disease provider in Hillsborough, New Jersey. Dr. Dwivedi is rated as a Distinguished provider by MediFind in the treatment of Streptococcal Group B Infection. His top areas of expertise are Sepsis, Methicillin-Resistant Staphylococcus Aureus (MRSA), COVID-19, and Multisystem Inflammatory Syndrome in Children (MIS-C). Dr. Dwivedi is currently accepting new patients.

Distinguished in Streptococcal Group B Infection
Dr. Danya J. Wenzler
Infectious Disease | Hospital Medicine
Distinguished in Streptococcal Group B Infection
Dr. Danya J. Wenzler
Infectious Disease | Hospital Medicine

Zufall Health Center, Inc

18 W Blackwell St, 
Dover, NJ 
 (28.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Danya Wenzler is an Infectious Disease specialist and a Hospital Medicine provider in Dover, New Jersey. Dr. Wenzler is rated as a Distinguished provider by MediFind in the treatment of Streptococcal Group B Infection. Her top areas of expertise are Sepsis, Pneumonia, Lymphangitis, and Streptococcal Group B Infection. Dr. Wenzler is currently accepting new patients.

Distinguished in Streptococcal Group B Infection
Dr. Stephen J. Williams
Infectious Disease
Distinguished in Streptococcal Group B Infection
Dr. Stephen J. Williams
Infectious Disease

Id Care LLC

105 Raider Blvd, Suite 101, 
Hillsborough, NJ 
 (7.6 miles away)
908-281-0221
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Williams is an Infectious Disease provider in Hillsborough, New Jersey. Dr. Williams is rated as a Distinguished provider by MediFind in the treatment of Streptococcal Group B Infection. His top areas of expertise are Sepsis, Cellulitis, Lymphangitis, and Infective Endocarditis. Dr. Williams is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nahass's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile